首页 > 最新文献

中国当代儿科杂志最新文献

英文 中文
[A case report of retroperitoneal infantile fibrosarcoma with RBPMS-NTRK3 fusion gene positivity]. [腹膜后婴儿纤维肉瘤合并RBPMS-NTRK3融合基因阳性1例]。
Q3 Medicine Pub Date : 2025-12-15 DOI: 10.7499/j.issn.1008-8830.2504143
Xin-Yi Zhou, Jian Jiang, Ling-Zhen Wang, Jun-Hong Guo

A 3-month-old female infant was admitted for incessant crying for 3 days. Examination revealed a rapidly growing massive retroperitoneal mass that was difficult to resect. Needle biopsy confirmed infantile fibrosarcoma. Initial chemotherapy with the VAC regimen (vincristine, actinomycin D, and cyclophosphamide) was administered, but the response was poor. The common fusion in infantile fibrosarcoma is ETV6-NTRK3, and next-generation sequencing detected an RBPMS-NTRK3 gene fusion in this patient. To our knowledge, this is the first reported case of infantile fibrosarcoma with RBPMS-NTRK3 fusion in China. Treatment with larotrectinib resulted in marked tumor shrinkage.

一名3个月大的女婴因连续哭闹3天入院。检查发现腹膜后快速生长的巨大肿块,难以切除。针活检证实为婴儿纤维肉瘤。初始化疗采用VAC方案(长春新碱、放线菌素D和环磷酰胺),但疗效不佳。婴儿纤维肉瘤中常见的融合是ETV6-NTRK3,新一代测序在该患者中检测到RBPMS-NTRK3基因融合。据我们所知,这是中国第一例报道的RBPMS-NTRK3融合的婴儿纤维肉瘤。larorectinib治疗导致肿瘤明显缩小。
{"title":"[A case report of retroperitoneal infantile fibrosarcoma with <i>RBPMS-NTRK3</i> fusion gene positivity].","authors":"Xin-Yi Zhou, Jian Jiang, Ling-Zhen Wang, Jun-Hong Guo","doi":"10.7499/j.issn.1008-8830.2504143","DOIUrl":"10.7499/j.issn.1008-8830.2504143","url":null,"abstract":"<p><p>A 3-month-old female infant was admitted for incessant crying for 3 days. Examination revealed a rapidly growing massive retroperitoneal mass that was difficult to resect. Needle biopsy confirmed infantile fibrosarcoma. Initial chemotherapy with the VAC regimen (vincristine, actinomycin D, and cyclophosphamide) was administered, but the response was poor. The common fusion in infantile fibrosarcoma is <i>ETV6-NTRK3</i>, and next-generation sequencing detected an <i>RBPMS</i>-<i>NTRK3</i> gene fusion in this patient. To our knowledge, this is the first reported case of infantile fibrosarcoma with <i>RBPMS-NTRK3</i> fusion in China. Treatment with larotrectinib resulted in marked tumor shrinkage.</p>","PeriodicalId":39792,"journal":{"name":"中国当代儿科杂志","volume":"27 12","pages":"1544-1548"},"PeriodicalIF":0.0,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12708064/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145769625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Development of dynamic multi-time-point clinical prediction models for bronchopulmonary dysplasia in preterm infants with gestational age < 32 weeks]. [建立胎龄< 32周早产儿支气管肺发育不良多时间点动态临床预测模型]。
Q3 Medicine Pub Date : 2025-12-15 DOI: 10.7499/j.issn.1008-8830.2503200
Wen Li, Xue-Fei Zhang, Xiao-Ri He, Tao Wang, Jing-Tao Hu, Wen Li, Qing-Yi Dong, Xiao-Yun Gong, Yong-Hui Yang, Ping-Yang Chen

Objectives: To develop dynamic prediction models based on multiple postnatal time points to support early diagnosis and individualized intervention for bronchopulmonary dysplasia (BPD) in preterm infants with gestational age < 32 weeks.

Methods: Clinical data of 472 preterm infants with gestational age <32 weeks admitted to the Second Xiangya Hospital of Central South University between January 2016 and November 2020 were retrospectively analyzed. Multivariable logistic regression was applied to develop five independent prediction models at postnatal days 1, 7, 14, 21, and 28. The performance of the models was assessed using the area under the receiver operating characteristic curve (AUC) and the Hosmer-Lemeshow test.

Results: Baseline characteristics such as gestational age and birth weight differed significantly between the BPD group (n=147) and the non-BPD group (n=325) (P<0.05). Predictors of BPD evolved across time points: on day 1, key predictors included gestational age, birth weight, Score for Neonatal Acute Physiology II (SNAP-II), invasive mechanical ventilation, and fraction of inspired oxygen >30%; by day 7, additional variables emerged, including fasting duration >2 days, mean feeding advancement rate <8.5 mL/(kg·d), neonatal respiratory distress syndrome, apnea of prematurity, and positive sputum culture; from day 14 onward, nutrition- and treatment-related indicators were incorporated additionally. The models demonstrated good discrimination at postnatal days 1, 7, 14, 21, and 28, with AUCs of 0.917, 0.927, 0.939, 0.944, and 0.968, respectively, and good calibration (Hosmer-Lemeshow P>0.05). Internal validation showed AUCs ranging from 0.899 to 0.958, indicating robust performance.

Conclusions: Dynamic postnatal prediction models incorporating indicators spanning perinatal factors, respiratory support, nutritional management, and therapeutic interventions demonstrate high predictive performance and facilitate dynamic risk assessment for BPD in preterm infants with gestational age < 32 weeks.

目的:建立基于产后多个时间点的动态预测模型,为胎龄< 32周早产儿支气管肺发育不良(BPD)的早期诊断和个体化干预提供支持。结果:BPD组(n=147)与非BPD组(n=325)的胎龄、出生体重等基线特征差异显著(P = 30%),到第7天,出现了其他变量,包括禁食时间>2天,平均喂养提前率P>0.05)。内部验证auc范围为0.899 ~ 0.958,性能稳健。结论:包含围产期因素、呼吸支持、营养管理和治疗干预等指标的动态产后预测模型具有较高的预测性能,有助于对胎龄< 32周的早产儿进行BPD的动态风险评估。
{"title":"[Development of dynamic multi-time-point clinical prediction models for bronchopulmonary dysplasia in preterm infants with gestational age < 32 weeks].","authors":"Wen Li, Xue-Fei Zhang, Xiao-Ri He, Tao Wang, Jing-Tao Hu, Wen Li, Qing-Yi Dong, Xiao-Yun Gong, Yong-Hui Yang, Ping-Yang Chen","doi":"10.7499/j.issn.1008-8830.2503200","DOIUrl":"10.7499/j.issn.1008-8830.2503200","url":null,"abstract":"<p><strong>Objectives: </strong>To develop dynamic prediction models based on multiple postnatal time points to support early diagnosis and individualized intervention for bronchopulmonary dysplasia (BPD) in preterm infants with gestational age < 32 weeks.</p><p><strong>Methods: </strong>Clinical data of 472 preterm infants with gestational age <32 weeks admitted to the Second Xiangya Hospital of Central South University between January 2016 and November 2020 were retrospectively analyzed. Multivariable logistic regression was applied to develop five independent prediction models at postnatal days 1, 7, 14, 21, and 28. The performance of the models was assessed using the area under the receiver operating characteristic curve (AUC) and the Hosmer-Lemeshow test.</p><p><strong>Results: </strong>Baseline characteristics such as gestational age and birth weight differed significantly between the BPD group (<i>n</i>=147) and the non-BPD group (<i>n</i>=325) (<i>P</i><0.05). Predictors of BPD evolved across time points: on day 1, key predictors included gestational age, birth weight, Score for Neonatal Acute Physiology II (SNAP-II), invasive mechanical ventilation, and fraction of inspired oxygen >30%; by day 7, additional variables emerged, including fasting duration >2 days, mean feeding advancement rate <8.5 mL/(kg·d), neonatal respiratory distress syndrome, apnea of prematurity, and positive sputum culture; from day 14 onward, nutrition- and treatment-related indicators were incorporated additionally. The models demonstrated good discrimination at postnatal days 1, 7, 14, 21, and 28, with AUCs of 0.917, 0.927, 0.939, 0.944, and 0.968, respectively, and good calibration (Hosmer-Lemeshow <i>P</i>>0.05). Internal validation showed AUCs ranging from 0.899 to 0.958, indicating robust performance.</p><p><strong>Conclusions: </strong>Dynamic postnatal prediction models incorporating indicators spanning perinatal factors, respiratory support, nutritional management, and therapeutic interventions demonstrate high predictive performance and facilitate dynamic risk assessment for BPD in preterm infants with gestational age < 32 weeks.</p>","PeriodicalId":39792,"journal":{"name":"中国当代儿科杂志","volume":"27 12","pages":"1464-1474"},"PeriodicalIF":0.0,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12708071/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145769351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Efficacy and safety of ibuprofen for the treatment of patent ductus arteriosus in preterm infants of different postnatal ages]. [布洛芬治疗不同出生年龄早产儿动脉导管未闭的疗效和安全性]。
Q3 Medicine Pub Date : 2025-12-15 DOI: 10.7499/j.issn.1008-8830.2504023
Di Wen, Yang Liu, Ping-Ren Chen, Tao Fan, Ke He

Objectives: To evaluate the efficacy and safety of ibuprofen in treating hemodynamically significant patent ductus arteriosus (hsPDA) in preterm infants of different postnatal ages at treatment initiation.

Methods: Clinical records of infants with gestational age <37 weeks who received ibuprofen for hsPDA in the Department of Neonatology, Fourth Hospital of Shijiazhuang, from January 2020 to December 2023 were retrospectively reviewed. One hundred eligible infants were divided by the postnatal age at the first ibuprofen administration into three groups: group A (≤4 days), group B (5-7 days), and group C (>7 days). Clinical efficacy and safety indicators were compared among groups.

Results: After treatment, cure rates were 92% in group A, 72% in group B, and 60% in group C, and effective rates were 8%, 25%, and 33%, respectively. Differences in clinical efficacy among the three groups were statistically significant (P<0.05). No significant differences were observed among groups in the incidence of pulmonary hemorrhage, gastrointestinal bleeding, cholestasis, bronchopulmonary dysplasia, necrotizing enterocolitis, intracranial hemorrhage, or acute kidney injury (P>0.05).

Conclusions: For hsPDA requiring pharmacologic therapy, earlier oral ibuprofen administration yields a higher ductal closure rate and does not increase the incidence of adverse events.

目的:评价布洛芬治疗开始时不同出生年龄早产儿血流动力学显著性动脉导管未闭(hsPDA)的疗效和安全性。方法:收集胎龄为7天的新生儿临床资料。各组间临床疗效及安全性指标比较。结果:治疗后,A组治愈率92%,B组治愈率72%,C组治愈率60%,有效率分别为8%、25%、33%。三组临床疗效比较,差异均有统计学意义(p < 0.05)。结论:对于需要药物治疗的hsPDA,早期口服布洛芬可提高导管闭合率,且不增加不良事件的发生率。
{"title":"[Efficacy and safety of ibuprofen for the treatment of patent ductus arteriosus in preterm infants of different postnatal ages].","authors":"Di Wen, Yang Liu, Ping-Ren Chen, Tao Fan, Ke He","doi":"10.7499/j.issn.1008-8830.2504023","DOIUrl":"10.7499/j.issn.1008-8830.2504023","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate the efficacy and safety of ibuprofen in treating hemodynamically significant patent ductus arteriosus (hsPDA) in preterm infants of different postnatal ages at treatment initiation.</p><p><strong>Methods: </strong>Clinical records of infants with gestational age <37 weeks who received ibuprofen for hsPDA in the Department of Neonatology, Fourth Hospital of Shijiazhuang, from January 2020 to December 2023 were retrospectively reviewed. One hundred eligible infants were divided by the postnatal age at the first ibuprofen administration into three groups: group A (≤4 days), group B (5-7 days), and group C (>7 days). Clinical efficacy and safety indicators were compared among groups.</p><p><strong>Results: </strong>After treatment, cure rates were 92% in group A, 72% in group B, and 60% in group C, and effective rates were 8%, 25%, and 33%, respectively. Differences in clinical efficacy among the three groups were statistically significant (<i>P</i><0.05). No significant differences were observed among groups in the incidence of pulmonary hemorrhage, gastrointestinal bleeding, cholestasis, bronchopulmonary dysplasia, necrotizing enterocolitis, intracranial hemorrhage, or acute kidney injury (<i>P</i>>0.05).</p><p><strong>Conclusions: </strong>For hsPDA requiring pharmacologic therapy, earlier oral ibuprofen administration yields a higher ductal closure rate and does not increase the incidence of adverse events.</p>","PeriodicalId":39792,"journal":{"name":"中国当代儿科杂志","volume":"27 12","pages":"1482-1486"},"PeriodicalIF":0.0,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12708072/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145769366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Research progress on biologics and therapeutic drug monitoring in pediatric inflammatory bowel disease]. [儿童炎症性肠病生物制剂及治疗药物监测研究进展]。
Q3 Medicine Pub Date : 2025-12-15 DOI: 10.7499/j.issn.1008-8830.2504199
Ting-Ting Pan, Hong-Lan Yang, Shi-Hai Zhou, Hui Sun

The incidence of pediatric inflammatory bowel disease (IBD) is rising, with an especially high proportion of early-onset cases in Asia. Conventional treatments such as glucocorticoids and immunosuppressants have limited efficacy and notable adverse effects, whereas biologic therapies substantially improve remission rates and quality of life. Therapeutic drug monitoring (TDM), by assessing trough concentrations and anti-drug antibodies, enables individualized dose optimization, reduces immunogenicity, and prolongs treatment persistence. However, challenges remain, including insufficient standardization and the lack of pediatric-specific concentration thresholds. This review summarizes recent advances in biologics and TDM in pediatric IBD to inform precision treatment.

儿童炎症性肠病(IBD)的发病率正在上升,亚洲早发病例的比例尤其高。常规治疗如糖皮质激素和免疫抑制剂的疗效有限,副作用明显,而生物治疗可显著提高缓解率和生活质量。治疗性药物监测(TDM)通过评估谷浓度和抗药物抗体,实现个体化剂量优化,降低免疫原性,延长治疗持久性。然而,挑战仍然存在,包括标准化不足和缺乏儿科特异性浓度阈值。本文综述了生物制剂和TDM治疗小儿IBD的最新进展,为精准治疗提供参考。
{"title":"[Research progress on biologics and therapeutic drug monitoring in pediatric inflammatory bowel disease].","authors":"Ting-Ting Pan, Hong-Lan Yang, Shi-Hai Zhou, Hui Sun","doi":"10.7499/j.issn.1008-8830.2504199","DOIUrl":"10.7499/j.issn.1008-8830.2504199","url":null,"abstract":"<p><p>The incidence of pediatric inflammatory bowel disease (IBD) is rising, with an especially high proportion of early-onset cases in Asia. Conventional treatments such as glucocorticoids and immunosuppressants have limited efficacy and notable adverse effects, whereas biologic therapies substantially improve remission rates and quality of life. Therapeutic drug monitoring (TDM), by assessing trough concentrations and anti-drug antibodies, enables individualized dose optimization, reduces immunogenicity, and prolongs treatment persistence. However, challenges remain, including insufficient standardization and the lack of pediatric-specific concentration thresholds. This review summarizes recent advances in biologics and TDM in pediatric IBD to inform precision treatment.</p>","PeriodicalId":39792,"journal":{"name":"中国当代儿科杂志","volume":"27 12","pages":"1556-1562"},"PeriodicalIF":0.0,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12708078/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145769375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Effect of rituximab combined with short-course glucocorticoid therapy on cellular immunity and cytokines in children with new-onset nephrotic syndrome]. [利妥昔单抗联合短期糖皮质激素治疗对新发肾病综合征患儿细胞免疫及细胞因子的影响]。
Q3 Medicine Pub Date : 2025-12-15 DOI: 10.7499/j.issn.1008-8830.2504028
Ting-Ting Yuan, Bing-Bing Zhu, Yan Li, Rui-Feng Zhang, Shan Qiu, Juan Lyu, Su-Qin Zhou

Objectives: To explore the effect of rituximab on cellular immunity and cytokines in children with new-onset steroid-sensitive nephrotic syndrome (SSNS).

Methods: Clinical data of 60 children with new-onset SSNS treated at Xuzhou Children's Hospital from December 2021 to March 2023 were retrospectively analyzed. Children were allocated according to rituximab use into a control group (no rituximab) and an observation group (rituximab). The relapse rate, T-lymphocyte subsets and cytokines before and after treatment, and the incidence of adverse reactions were compared between groups.

Results: The relapse rate was lower in the observation group than in the control group (27% vs 73%, P<0.05). After treatment, CD3+ and CD4+ T-lymphocyte counts, the CD4+/CD8+ ratio, and serum interleukin-2 increased in the observation group and were higher than in the control group (P<0.05). Interleukin-6 and tumor necrosis factor-α levels decreased after treatment in the observation group and were lower than in the control group (P<0.05). After treatment, CD8+ T-lymphocyte counts decreased, interferon-γ increased, and interleukin-10 decreased in both groups, with no significant differences between the two groups (P>0.05). The incidence of adverse reactions did not differ significantly between the two groups (P>0.05).

Conclusions: Rituximab can reduce the relapse rate in children with new-onset nephrotic syndrome and shows good safety. Its therapeutic effect is achieved by regulating the number and function of T cells and by modulating the anti-inflammatory effects of cytokines.

目的:探讨利妥昔单抗对新发类固醇敏感性肾病综合征(SSNS)患儿细胞免疫及细胞因子的影响。方法:回顾性分析2021年12月至2023年3月徐州市儿童医院收治的60例新发SSNS患儿的临床资料。根据利妥昔单抗的使用情况将患儿分为对照组(未使用利妥昔单抗)和观察组(利妥昔单抗)。比较两组患者治疗前后复发率、t淋巴细胞亚群、细胞因子及不良反应发生率。结果:观察组复发率低于对照组(27% vs 73%),观察组P+、CD4+ t淋巴细胞计数、CD4+/CD8+比值、血清白介素-2升高,均高于对照组(两组PP+ t淋巴细胞计数降低、干扰素-γ升高、白介素-10降低,两组间差异无统计学意义(P < 0.05)。两组不良反应发生率差异无统计学意义(P < 0.05)。结论:利妥昔单抗可降低儿童新发肾病综合征的复发率,安全性好。其治疗效果是通过调节T细胞的数量和功能以及调节细胞因子的抗炎作用来实现的。
{"title":"[Effect of rituximab combined with short-course glucocorticoid therapy on cellular immunity and cytokines in children with new-onset nephrotic syndrome].","authors":"Ting-Ting Yuan, Bing-Bing Zhu, Yan Li, Rui-Feng Zhang, Shan Qiu, Juan Lyu, Su-Qin Zhou","doi":"10.7499/j.issn.1008-8830.2504028","DOIUrl":"10.7499/j.issn.1008-8830.2504028","url":null,"abstract":"<p><strong>Objectives: </strong>To explore the effect of rituximab on cellular immunity and cytokines in children with new-onset steroid-sensitive nephrotic syndrome (SSNS).</p><p><strong>Methods: </strong>Clinical data of 60 children with new-onset SSNS treated at Xuzhou Children's Hospital from December 2021 to March 2023 were retrospectively analyzed. Children were allocated according to rituximab use into a control group (no rituximab) and an observation group (rituximab). The relapse rate, T-lymphocyte subsets and cytokines before and after treatment, and the incidence of adverse reactions were compared between groups.</p><p><strong>Results: </strong>The relapse rate was lower in the observation group than in the control group (27% vs 73%, <i>P</i><0.05). After treatment, CD3<sup>+</sup> and CD4<sup>+</sup> T-lymphocyte counts, the CD4<sup>+</sup>/CD8<sup>+</sup> ratio, and serum interleukin-2 increased in the observation group and were higher than in the control group (<i>P</i><0.05). Interleukin-6 and tumor necrosis factor-α levels decreased after treatment in the observation group and were lower than in the control group (<i>P</i><0.05). After treatment, CD8<sup>+</sup> T-lymphocyte counts decreased, interferon-γ increased, and interleukin-10 decreased in both groups, with no significant differences between the two groups (<i>P</i>>0.05). The incidence of adverse reactions did not differ significantly between the two groups (<i>P</i>>0.05).</p><p><strong>Conclusions: </strong>Rituximab can reduce the relapse rate in children with new-onset nephrotic syndrome and shows good safety. Its therapeutic effect is achieved by regulating the number and function of T cells and by modulating the anti-inflammatory effects of cytokines.</p>","PeriodicalId":39792,"journal":{"name":"中国当代儿科杂志","volume":"27 12","pages":"1500-1505"},"PeriodicalIF":0.0,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12708061/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145769356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Expert recommendations on antenatal counseling for extremely preterm infants]. [专家对极早产儿产前咨询的建议]。
Q3 Medicine Pub Date : 2025-12-15 DOI: 10.7499/j.issn.1008-8830.2506141

With continuous advancements in neonatal care in China, the survival rate of extremely preterm infants has markedly increased in recent years. However, the proportion of voluntary withdrawal of treatment for extremely preterm infants remains relatively high. To further improve the overall treatment success rate for extremely preterm infants in Hunan Province, the Hunan Neonatal Medical Quality Control Center, in collaboration with the Perinatal Committee of the Hunan Medical Association, organized experts to develop recommendations on antenatal counseling for extremely preterm infants. These recommendations aim to standardize antenatal counseling procedures, enhance the scientific rigor and consistency of clinical decision-making, and improve survival outcomes.

近年来,随着中国新生儿护理水平的不断提高,极早产儿的存活率显著提高。然而,极度早产儿自愿退出治疗的比例仍然相对较高。为进一步提高湖南省极早产儿的整体治疗成功率,湖南省新生儿医疗质量控制中心与湖南省医学会围产期委员会合作,组织专家制定了极早产儿产前咨询建议。这些建议旨在规范产前咨询程序,提高临床决策的科学性和一致性,改善生存结果。
{"title":"[Expert recommendations on antenatal counseling for extremely preterm infants].","authors":"","doi":"10.7499/j.issn.1008-8830.2506141","DOIUrl":"10.7499/j.issn.1008-8830.2506141","url":null,"abstract":"<p><p>With continuous advancements in neonatal care in China, the survival rate of extremely preterm infants has markedly increased in recent years. However, the proportion of voluntary withdrawal of treatment for extremely preterm infants remains relatively high. To further improve the overall treatment success rate for extremely preterm infants in Hunan Province, the Hunan Neonatal Medical Quality Control Center, in collaboration with the Perinatal Committee of the Hunan Medical Association, organized experts to develop recommendations on antenatal counseling for extremely preterm infants. These recommendations aim to standardize antenatal counseling procedures, enhance the scientific rigor and consistency of clinical decision-making, and improve survival outcomes.</p>","PeriodicalId":39792,"journal":{"name":"中国当代儿科杂志","volume":"27 12","pages":"1444-1450"},"PeriodicalIF":0.0,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12708060/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145769413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Clinical and genetic characteristics of 14 children with sodium taurocholate co-transporting polypeptide deficiency]. [14例牛磺胆酸钠共转运多肽缺乏症患儿的临床及遗传特点]。
Q3 Medicine Pub Date : 2025-12-15 DOI: 10.7499/j.issn.1008-8830.2503129
Rui-Xue Ma, Wen-Hai Luo, Yi-Lin Dai, Gui-Xian Li, Fei Wang, Ou Jiang, Yin-Hong Zhang, Yun-Fen Tian

Objectives: To summarize the clinical and genetic characteristics of children with sodium taurocholate co-transporting polypeptide (NTCP) deficiency.

Methods: Clinical data of children with NTCP deficiency diagnosed and treated at the First People's Hospital of Yunnan Province from July 2022 to March 2025 were retrospectively analyzed.

Results: A total of 14 children were included (6 males, 8 females), all with normal growth and development. Reasons for initial consultation included elevated serum bile acids in 7 cases, jaundice in 4 cases, cholestatic hepatitis in 1 case, and one case each of pneumonia and cow's milk protein allergy. At the first visit, all patients had elevated serum total bile acids beyond the normal range, with a mean of 152.5 μmol/L. Elevated alanine aminotransferase was observed in 1 case, elevated aspartate aminotransferase in 2 cases, and elevated total bilirubin in 10 cases. Genetic sequencing revealed that all children carried the homozygous SLC10A1 variant c.800C>T (p.Ser267Phe), classified as likely pathogenic.

Conclusions: NTCP deficiency often lacks obvious clinical symptoms and signs. Some children present with transient hyperbilirubinemia, cholestasis, or other liver function abnormalities. Persistent isolated elevation of serum bile acids warrants suspicion for this disease. Biallelic pathogenic variants in SLC10A1 constitute the basis for definitive diagnosis. There is no specific treatment for this disease, and management is mainly symptomatic.

目的:总结牛磺胆酸钠共转运多肽(NTCP)缺乏症患儿的临床及遗传特点。方法:回顾性分析2022年7月至2025年3月云南省第一人民医院诊治的NTCP缺乏症患儿的临床资料。结果:共纳入14例患儿(男6例,女8例),均生长发育正常。初诊原因:血清胆汁酸升高7例,黄疸4例,胆汁淤积性肝炎1例,肺炎和牛奶蛋白过敏各1例。首次就诊时,所有患者血清总胆汁酸均高于正常范围,平均值为152.5 μmol/L。谷丙转氨酶升高1例,天冬氨酸转氨酶升高2例,总胆红素升高10例。基因测序显示,所有儿童携带纯合子SLC10A1变异c.800C>T (p.Ser267Phe),分类为可能致病。结论:NTCP缺乏症往往缺乏明显的临床症状和体征。部分患儿表现为短暂性高胆红素血症、胆汁淤积或其他肝功能异常。持续孤立的血清胆汁酸升高值得怀疑这种疾病。SLC10A1的双等位致病变异构成了明确诊断的基础。这种疾病没有专门的治疗方法,治疗主要是对症治疗。
{"title":"[Clinical and genetic characteristics of 14 children with sodium taurocholate co-transporting polypeptide deficiency].","authors":"Rui-Xue Ma, Wen-Hai Luo, Yi-Lin Dai, Gui-Xian Li, Fei Wang, Ou Jiang, Yin-Hong Zhang, Yun-Fen Tian","doi":"10.7499/j.issn.1008-8830.2503129","DOIUrl":"10.7499/j.issn.1008-8830.2503129","url":null,"abstract":"<p><strong>Objectives: </strong>To summarize the clinical and genetic characteristics of children with sodium taurocholate co-transporting polypeptide (NTCP) deficiency.</p><p><strong>Methods: </strong>Clinical data of children with NTCP deficiency diagnosed and treated at the First People's Hospital of Yunnan Province from July 2022 to March 2025 were retrospectively analyzed.</p><p><strong>Results: </strong>A total of 14 children were included (6 males, 8 females), all with normal growth and development. Reasons for initial consultation included elevated serum bile acids in 7 cases, jaundice in 4 cases, cholestatic hepatitis in 1 case, and one case each of pneumonia and cow's milk protein allergy. At the first visit, all patients had elevated serum total bile acids beyond the normal range, with a mean of 152.5 μmol/L. Elevated alanine aminotransferase was observed in 1 case, elevated aspartate aminotransferase in 2 cases, and elevated total bilirubin in 10 cases. Genetic sequencing revealed that all children carried the homozygous <i>SLC10A1</i> variant c.800C>T (p.Ser267Phe), classified as likely pathogenic.</p><p><strong>Conclusions: </strong>NTCP deficiency often lacks obvious clinical symptoms and signs. Some children present with transient hyperbilirubinemia, cholestasis, or other liver function abnormalities. Persistent isolated elevation of serum bile acids warrants suspicion for this disease. Biallelic pathogenic variants in <i>SLC10A1</i> constitute the basis for definitive diagnosis. There is no specific treatment for this disease, and management is mainly symptomatic.</p>","PeriodicalId":39792,"journal":{"name":"中国当代儿科杂志","volume":"27 12","pages":"1514-1519"},"PeriodicalIF":0.0,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12708075/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145769582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Electroencephalographic assessment of the relationship between frontal alpha asymmetry and emotion dysregulation in children with attention deficit hyperactivity disorder]. [注意缺陷多动障碍儿童额叶α不对称与情绪失调关系的脑电图评估]。
Q3 Medicine Pub Date : 2025-12-15 DOI: 10.7499/j.issn.1008-8830.2506048
Lei Chen, Li-Li Zhao, Xiao-Chen Wu, Hong-Yuan Li, Wei-Wei Zhang

Objectives: To explore the relationship between frontal alpha asymmetry (FAA) assessed by electroencephalogram (EEG) and emotion dysregulation (ED) in children with attention deficit hyperactivity disorder (ADHD).

Methods: Children with ADHD admitted to Fuyang Women and Children's Hospital from September 2021 to December 2024 were prospectively enrolled (n=104). Based on the Achenbach Child Behavior Checklist (CBCL), participants were classified into an ED group (sum of three subscales <180; n=41) and a non-ED group (sum ≥180; n=63). Clinical data were collected, and the Chinese ADHD SNAP-IV parent version and the Weiss Functional Impairment Rating Scale-Parent Report were used. FAA was measured by EEG. Correlations between FAA in different regions and CBCL score were analyzed, and the predictive value of FAA for ED was evaluated with multivariable logistic regression and receiver operating characteristic curves.

Results: Compared with the non-ED group, the ED group had a higher proportion of the predominantly inattentive ADHD subtype, higher SNAP-IV total score, higher Weiss Functional Impairment Rating Scale-Parent Report total score, and higher FP1/FP2-FAA and C3/C4-FAA (P<0.05). FP1/FP2-FAA and C3/C4-FAA were negatively correlated with CBCL score (P<0.05). The multivariable logistic regression analysis showed that FP1/FP2-FAA and C3/C4-FAA were closely associated with ED in children with ADHD (P<0.05). The areas under the curve for predicting ED using FP1/FP2-FAA, C3/C4-FAA, and their combination were 0.827, 0.685, and 0.917, respectively (P<0.05), and the combined prediction had a higher area under the curve than either single marker (P<0.05). The FP1/FP2 FAA value in hyperactive-impulsive ADHD was lower than in combined-type ADHD and predominantly inattentive ADHD (P<0.05).

Conclusions: FP1/FP2-FAA and C3/C4-FAA are reliable neural markers of emotion dysregulation in children with ADHD, and their combination shows superior predictive performance. ADHD subtypes show distinct patterns of FAA-functional impairment associations.

目的:探讨注意缺陷多动障碍(ADHD)患儿脑电图(EEG)额叶α不对称(FAA)与情绪调节障碍(ED)的关系。方法:前瞻性纳入2021年9月至2024年12月阜阳市妇女儿童医院收治的ADHD儿童(n=104)。根据Achenbach儿童行为检查表(CBCL),将参与者分为ED组(三个分量表之和n=41)和非ED组(总和≥180;n=63)。收集临床资料,采用中文版ADHD SNAP-IV家长版和Weiss功能障碍评定量表-家长报告。脑电法测定FAA。分析不同地区FAA与CBCL评分的相关性,采用多变量logistic回归和受试者工作特征曲线评价FAA对ED的预测价值。结果:与非ED组相比,ED组ADHD亚型中注意力不集中占比较高,SNAP-IV总分较高,Weiss功能障碍评定量表-家长报告总分较高,FP1/FP2-FAA和C3/C4-FAA (ppppppp)较高。结论:FP1/FP2-FAA和C3/C4-FAA是ADHD儿童情绪失调的可靠神经标志物,两者联合预测效果较好。ADHD亚型表现出不同的faa -功能损害关联模式。
{"title":"[Electroencephalographic assessment of the relationship between frontal alpha asymmetry and emotion dysregulation in children with attention deficit hyperactivity disorder].","authors":"Lei Chen, Li-Li Zhao, Xiao-Chen Wu, Hong-Yuan Li, Wei-Wei Zhang","doi":"10.7499/j.issn.1008-8830.2506048","DOIUrl":"10.7499/j.issn.1008-8830.2506048","url":null,"abstract":"<p><strong>Objectives: </strong>To explore the relationship between frontal alpha asymmetry (FAA) assessed by electroencephalogram (EEG) and emotion dysregulation (ED) in children with attention deficit hyperactivity disorder (ADHD).</p><p><strong>Methods: </strong>Children with ADHD admitted to Fuyang Women and Children's Hospital from September 2021 to December 2024 were prospectively enrolled (<i>n</i>=104). Based on the Achenbach Child Behavior Checklist (CBCL), participants were classified into an ED group (sum of three subscales <180; <i>n</i>=41) and a non-ED group (sum ≥180; <i>n</i>=63). Clinical data were collected, and the Chinese ADHD SNAP-IV parent version and the Weiss Functional Impairment Rating Scale-Parent Report were used. FAA was measured by EEG. Correlations between FAA in different regions and CBCL score were analyzed, and the predictive value of FAA for ED was evaluated with multivariable logistic regression and receiver operating characteristic curves.</p><p><strong>Results: </strong>Compared with the non-ED group, the ED group had a higher proportion of the predominantly inattentive ADHD subtype, higher SNAP-IV total score, higher Weiss Functional Impairment Rating Scale-Parent Report total score, and higher FP1/FP2-FAA and C3/C4-FAA (<i>P</i><0.05). FP1/FP2-FAA and C3/C4-FAA were negatively correlated with CBCL score (<i>P</i><0.05). The multivariable logistic regression analysis showed that FP1/FP2-FAA and C3/C4-FAA were closely associated with ED in children with ADHD (<i>P</i><0.05). The areas under the curve for predicting ED using FP1/FP2-FAA, C3/C4-FAA, and their combination were 0.827, 0.685, and 0.917, respectively (<i>P</i><0.05), and the combined prediction had a higher area under the curve than either single marker (<i>P</i><0.05). The FP1/FP2 FAA value in hyperactive-impulsive ADHD was lower than in combined-type ADHD and predominantly inattentive ADHD (<i>P</i><0.05).</p><p><strong>Conclusions: </strong>FP1/FP2-FAA and C3/C4-FAA are reliable neural markers of emotion dysregulation in children with ADHD, and their combination shows superior predictive performance. ADHD subtypes show distinct patterns of FAA-functional impairment associations.</p>","PeriodicalId":39792,"journal":{"name":"中国当代儿科杂志","volume":"27 12","pages":"1493-1499"},"PeriodicalIF":0.0,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12708073/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145769346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Nasopharyngeal carcinoma in children: clinical analysis of 6 cases and literature review]. 儿童鼻咽癌6例临床分析及文献复习。
Q3 Medicine Pub Date : 2025-12-15 DOI: 10.7499/j.issn.1008-8830.2508083
Mei-Ling Tang, Wei-Ling Zhang, Yi-Zhuo Wang, Yi Zhang

Objectives: To study the clinical characteristics, imaging findings, pathological features, treatment methods, and prognosis of nasopharyngeal carcinoma in children.

Methods: The clinical data of 6 children (<18 years) with nasopharyngeal carcinoma admitted to the Department of Pediatrics, Beijing Tongren Hospital from March 2021 to February 2025 were retrospectively reviewed, and outcomes were followed up.

Results: All 6 patients were male. Age at onset ranged from 11 to 15 years, with a median of 12.5 years. The interval from onset to diagnosis was 1-6 months. The main clinical symptoms were cervical mass (4 cases, 67%) and headache (3 cases, 50%); some patients also had nasal congestion and rhinorrhea, epistaxis, or limited mouth opening. TNM staging was stage III in 4 cases and stage IVa in 2 cases. All patients had non-keratinizing undifferentiated nasopharyngeal carcinoma on pathology. Treatments included radiotherapy, chemotherapy, surgery, targeted therapy, and immunotherapy. By July 1, 2025, after comprehensive treatment, 5 patients (83%) achieved complete remission, and 1 patient (17%) experienced recurrence and progression and died.

Conclusions: Comprehensive treatment based on combined radiotherapy and chemotherapy is the mainstay for childhood nasopharyngeal carcinoma, overall prognosis is favorable, and long-term follow-up is required. Molecular targeted therapy and immunotherapy are expected to improve the prognosis of advanced nasopharyngeal carcinoma and require further research for validation.

目的:探讨儿童鼻咽癌的临床特点、影像学表现、病理特点、治疗方法及预后。方法:6例小儿临床资料(结果:6例患者均为男性。发病年龄11 ~ 15岁,中位12.5岁。发病至确诊间隔1 ~ 6个月。主要临床症状为宫颈肿块(4例,67%)、头痛(3例,50%);一些患者还出现鼻塞、鼻漏、鼻出血或张嘴受限。TNM分期为III期4例,IVa期2例。所有患者病理均为非角化未分化鼻咽癌。治疗方法包括放疗、化疗、手术、靶向治疗和免疫治疗。截至2025年7月1日,经综合治疗,5例患者(83%)完全缓解,1例患者(17%)复发进展死亡。结论:以放化疗联合治疗为主的综合治疗是儿童鼻咽癌的主要治疗方法,总体预后良好,需长期随访。分子靶向治疗和免疫治疗有望改善晚期鼻咽癌的预后,需要进一步的研究来验证。
{"title":"[Nasopharyngeal carcinoma in children: clinical analysis of 6 cases and literature review].","authors":"Mei-Ling Tang, Wei-Ling Zhang, Yi-Zhuo Wang, Yi Zhang","doi":"10.7499/j.issn.1008-8830.2508083","DOIUrl":"10.7499/j.issn.1008-8830.2508083","url":null,"abstract":"<p><strong>Objectives: </strong>To study the clinical characteristics, imaging findings, pathological features, treatment methods, and prognosis of nasopharyngeal carcinoma in children.</p><p><strong>Methods: </strong>The clinical data of 6 children (<18 years) with nasopharyngeal carcinoma admitted to the Department of Pediatrics, Beijing Tongren Hospital from March 2021 to February 2025 were retrospectively reviewed, and outcomes were followed up.</p><p><strong>Results: </strong>All 6 patients were male. Age at onset ranged from 11 to 15 years, with a median of 12.5 years. The interval from onset to diagnosis was 1-6 months. The main clinical symptoms were cervical mass (4 cases, 67%) and headache (3 cases, 50%); some patients also had nasal congestion and rhinorrhea, epistaxis, or limited mouth opening. TNM staging was stage III in 4 cases and stage IVa in 2 cases. All patients had non-keratinizing undifferentiated nasopharyngeal carcinoma on pathology. Treatments included radiotherapy, chemotherapy, surgery, targeted therapy, and immunotherapy. By July 1, 2025, after comprehensive treatment, 5 patients (83%) achieved complete remission, and 1 patient (17%) experienced recurrence and progression and died.</p><p><strong>Conclusions: </strong>Comprehensive treatment based on combined radiotherapy and chemotherapy is the mainstay for childhood nasopharyngeal carcinoma, overall prognosis is favorable, and long-term follow-up is required. Molecular targeted therapy and immunotherapy are expected to improve the prognosis of advanced nasopharyngeal carcinoma and require further research for validation.</p>","PeriodicalId":39792,"journal":{"name":"中国当代儿科杂志","volume":"27 12","pages":"1520-1525"},"PeriodicalIF":0.0,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12708069/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145769405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Best evidence summary for management of sleep disorders in children with attention deficit hyperactivity disorder]. [儿童注意缺陷多动障碍睡眠障碍管理的最佳证据总结]。
Q3 Medicine Pub Date : 2025-11-15 DOI: 10.7499/j.issn.1008-8830.2505076
Yuan-Ting Lin, Li-Hui Luo, Tong-Qin Peng, Chun-Wen Tan, Hui Lei

Objectives: To evaluate and integrate evidence on the management of sleep disorders in children with attention deficit hyperactivity disorder (ADHD).

Methods: Literature was retrieved based on the 6S model, and evidence related to sleep disorder management in children with ADHD was extracted from the included references.

Results: A total of 17 studies were included, from which 16 pieces of evidence were extracted. Of these, 6 were classified as Level 1 evidence and 10 as Level 5. The evidence covered screening, assessment, non-pharmacological interventions, pharmacological interventions, follow-up, and multidisciplinary collaboration.

Conclusions: This study integrated evidence on the management of sleep disorders in children with ADHD using an evidence-based approach, providing an evidence-based foundation for managing sleep disorders in this population.

目的:评价和整合注意缺陷多动障碍(ADHD)患儿睡眠障碍的治疗证据。方法:采用6S模型进行文献检索,从纳入的文献中提取ADHD儿童睡眠障碍管理的相关证据。结果:共纳入17项研究,从中提取了16条证据。其中6项为一级证据,10项为五级证据。证据包括筛查、评估、非药物干预、药物干预、随访和多学科合作。结论:本研究采用循证方法整合了ADHD儿童睡眠障碍管理的证据,为该人群的睡眠障碍管理提供了循证基础。
{"title":"[Best evidence summary for management of sleep disorders in children with attention deficit hyperactivity disorder].","authors":"Yuan-Ting Lin, Li-Hui Luo, Tong-Qin Peng, Chun-Wen Tan, Hui Lei","doi":"10.7499/j.issn.1008-8830.2505076","DOIUrl":"10.7499/j.issn.1008-8830.2505076","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate and integrate evidence on the management of sleep disorders in children with attention deficit hyperactivity disorder (ADHD).</p><p><strong>Methods: </strong>Literature was retrieved based on the 6S model, and evidence related to sleep disorder management in children with ADHD was extracted from the included references.</p><p><strong>Results: </strong>A total of 17 studies were included, from which 16 pieces of evidence were extracted. Of these, 6 were classified as Level 1 evidence and 10 as Level 5. The evidence covered screening, assessment, non-pharmacological interventions, pharmacological interventions, follow-up, and multidisciplinary collaboration.</p><p><strong>Conclusions: </strong>This study integrated evidence on the management of sleep disorders in children with ADHD using an evidence-based approach, providing an evidence-based foundation for managing sleep disorders in this population.</p>","PeriodicalId":39792,"journal":{"name":"中国当代儿科杂志","volume":"27 11","pages":"1353-1359"},"PeriodicalIF":0.0,"publicationDate":"2025-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12688192/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145543129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
中国当代儿科杂志
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1